Marketgems Earnings Trader- Trading Strong or Weak Earnings Growth

[jjkool_01]

ATB.to, DD below, Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
Wednesday October 24, 9:30 am ET

QUEBEC, Oct. 24 /CNW Telbec/ - Atrium Innovations Inc. (TSX: ATB - News) will hold its quarterly conference call and webcast at 10 a.m. Eastern time on November 8, 2007. The call will follow the press release of Atrium's 2007 third quarter results issued earlier the previous day. Participants may access the call by using the following numbers: 416-644-3418, 514-807-8791 or 800-591-7539 or via the Company's website at www.atrium-innov.com in the "Investors" section.
====and======
ATB.to: worthy of further DD and a buy..Prior to this acquisition listed below, the share price of Atrium was 21.40 Canadian. It subsequently moved to 29.50 in six days. I has now pulled back well beyond where it should have and is a very atttractive buy at this level IMO. This is a global company. As the USD declines against most foreign currencies, we can do well since this trades on the Toronto Exchange. Your broker can place the order if you cannot do it online.
Current share price: $22.27 Canadian.
Target share price : $30 - 32 < 6 months
Initial target could be reached much sooner as this Q earnings should show the impact of the profit and revenue contributions from Mucos.

Financial Reports
http://www.atrium-innov.com/en/investisseurs/rapports.php

Acquisition PR
Atrium Acquires Mucos, a Market Leader of OTC and Dietary Supplements Products in Germany

All amounts are in U.S. dollars

Quebec City, Canada, July 12, 2007 – Atrium Innovations Inc. (TSX: ATB) today announced the acquisition, effective today, of German-based Mucos Emulsions GmbH. (“Mucos”). Mucos, whose main brand is WobenzymTM, has been marketing enzyme based products for over 50 years and had 2006 annual revenues of approximately €62 million (US$85 million). By acquiring Mucos, Atrium establishes its’ Health & Nutrition Division in Europe with a leading brand and gains a privileged access to the German market, the largest European market for dietary supplements. The transaction is immediately accretive, enabling Atrium to increase its normalized earnings before interest, income taxes, depreciation and amortization (EBITDA) by approximately US$27 million to about US$79 million on a pro forma basis and therefore also increasing fully diluted earnings per share by 45%. Following the transaction, Atrium’s pro forma revenues will exceed US$420 million.

“This strategic acquisition allows Atrium to establish a significant presence in Europe with a long established and leading brand in the fast growing health and nutrition market. This is the first step taken by the Health & Nutrition Division to achieve market leadership in Europe. It should
be followed by further acquisitions and strong organic growth as we did in the United States and Canada. Moreover, this acquisition marks a major step in our Company’s growth strategy aimed at positioning each of our two divisions as worldwide leaders,” stated Pierre Fitzgibbon, Atrium's President and Chief Executive Officer.

Under the agreement, Atrium will acquire Mucos for the total amount of €127.5 million
(US$175 million), representing approximately 6.5 times the normalized EBITDA generated by Mucos. The total amount will be paid in cash and will come from cash on hand and a newly negotiated credit facility of US$350 million that can be increased to US$425 million under certain conditions.

“As with all our previous acquisitions, the acquisition of Mucos generates immediate and significant added-value for our shareholders. As of March 31, 2007, on a pro forma basis, not only would revenues have increased from US$336 million to US$421 million, but EBITDA would also have grown by more than 50% to US$79 million. Also, fully diluted earnings per share would have increased by 45% to US$1.23 on a pro forma basis. Taking into account the profitability of operations, pro forma cash flows would have increased to US$41 million per annum from the current US$32 million,” underlined John Dempsey, Vice-President, Finance and Chief Financial Officer at Atrium.

A Strategic Acquisition
Mucos was established in Munich, Germany in 1949 and specializes in enzyme based products. Mucos’s lead product, WobenzymTM, is Germany's most popular natural anti-inflammatory product. The efficacy of WobenzymTM is proven by numerous clinical studies. Mucos’ products are mainly sold in Germany and Eastern Europe, but are also sold in Asia, Latin America and North America. The company has approximately 60 employees of which 42 are dedicated to sales and marketing. In 2006, Mucos had revenues and normalized EBITDA of approximately €62 million (US$85 million) and €20 million (US$27 million), respectively.

“Recognized across the industry for the quality and efficacy of its products, Mucos is experiencing growth and has excellent profit margins. The addition of the Mucos brand to Atrium’s US-based brands, Douglas Laboratories and Pure Encapsulations, provides Atrium with remarkable growth opportunities considering the complementarities of the international commercial networks. Mucos relies on a strong and growing sales force to cover Germany and uses distributors for other countries. We intend to optimize the market penetration of different territories based on the strengths of our existing operations,” stated Richard Bordeleau, President of Atrium’s Healthcare & Nutrition Division.

“In addition, Atrium will be able to benefit from the expertise and support of Mucos’ current management who will stay on to ensure the successful integration of the subsidiary and maintain its growth. Their vast operational and marketing expertise, as well as their excellent knowledge of the European market will be a valuable asset to the Company,” added Richard Bordeleau.

Conference Call on the Acquisition
Atrium will hold a conference call and webcast that will include a slide presentation to discuss the Mucos acquisition today at 2:00 p.m. Eastern time. Participants may access the call by using the following numbers: 416-644-3419, 514-807-8791 or 1-800-594-3615. The live webcast including the slide presentation is also available via the Company’s website at www.atrium innov.com in the "Investors" section. A replay of the webcast will also be available on our website for a period of 30 days.
========

About Atrium
Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 600 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-innov.com.
=============

Growth Strategy
Acquisition and In-Licensing of Products
Atrium Innovations' business and product development team focuses primarily on acquiring and in-licensing products. We work closely with our customers' research and development teams to identify specific market opportunities. Supported by an international network of consultants, our development team seeks technologies which complement our existing portfolio, answer unmet customer needs and help us establish relationships with new customers in new territories. Our knowledge of industry needs and regulatory requirements enables us to focus only on those scientific protocols needed to obtain regulatory approval and market acceptance. This allows us to reduce development costs and generally introduce acquired or in-licensed products in less than a year.

Internal Product Development
Atrium Innovations' internal product development team concentrates on product adaptations and improvements. Our team works on finding new applications or new formulations with existing active ingredients. Our development team is always studying new extraction procedures to isolate or enrich biologically active fractions.

Collaboration with Research-Based Organizations
Our long-term product pipeline strategy is to partner with research and development organizations. In addition to in-licensing, we expect those partnerships to provide us with a solid pipeline of innovative products in the long term. Atrium Innovations recently invested in Océanova, an independent research organization dedicated to screening marine biomass, primarily from the St-Lawrence River.

Company Acquisitions
Atrium Innovations' business development plan also includes a program for company acquisitions. The key features of the acquisition program are as follows:

acquisition of nutritional supplement products or companies;
acquisition of companies specializing in the manufacturing of active ingredients and specialty products;
acquisition of cosmetic active ingredient lines or companies.
============
Atrium Innovations Inc develops and produces innovative active ingredients for the cosmetics market.
Atrium's mission is to be a strategic supplier to leading brand owners and manufacturers, and, as such, Atrium has developed a differentiated business model focused on providing unique and comprehensive solutions. Atrium 's broad offering of active ingredients and speciality chemicals is complemented by a wide range of scientific, technical and regulatory support services.
These complementary products and value-added solutions which have enable Atrium to develop a unique level of intimacy with customers.
All the ingredients marketed are supported by rigorous scientific research and documentation: we do not compromise on quality. Some of our biotechnology products are derived from a molecular separation platform and manufactured in the company's laboratories in compliance with the highest standards. Other products were obtained by means of acquisitions or technology licensing from research centres and recognized biotechnology companies.

Our active cosmetic ingredients are designed to maintain the body's natural reactions, strengthen its defences against environmental aggression, delay the appearance of the signs of aging, and address other contemporary cosmetic challenges. Our ultimate goal is to offer consumers visible benefits that last.

Family of products
• Biotechnology: Atrium's biotechnological processes make it possible to create outsanding and biologically active polysaccharides. Abyssine®, Aldavine™ and Drieline®

• Marine: Unique and complete range of marine-derived cosmetic ingredients from algae extracts to marine mucopolysaccharides. MDI Complex®, MRT2, Lanablue®, Tensea-Lift™, Hydriame®, Hydroxan®, Homeosta-SEA: Homeo-Shield™, Homeo-Age™, Homeoxy™, Homeo-Soothe™

• Plant Extracts: Exclusive cosmetic ingredients derived from plants that are native from northern Canadian prairies, the African savanna and the Asian landscape. Canadian Willowherb™, Tyrostat™, Lanachrys®, Lanatellis®, Lanacityn®, LNST®, Hydralphatine Asia®, Hydralphatine 3P®

• Synthetic: Highly purified biomimetic peptides and enzymes, which act as natural effectors in the skin physiology. EUK-134®, Melitane®, Thymulen-4®, Melanostatine-5®, Kollaren® and ECM-Protect®

A number of products are also available in a preservative-free version specially designed with natural anti-oxidants and anti-microbial system to minimize the presence of preservative in final cosmetic formulas.

Atrium can rely on its subsidiaries Unipex and Multichem to provide support services related to the development, importation and distribution of speciality chemicals and active ingredients.
- Unipex holds the exclusive distribution rights to one of the broadest high value active ingredients and fine chemicals portfolio in France, with approximately 1 300 products primarily focused on the personal care, cosmetic and life sciences sector.
- Multichem is a leading Canadian chemicals distributor with a portfolio of approximately 800 exclusive products serving more than 900customers in Canada and Northeastern US.

Atrium has a network of distributors and professional agents in more than 50 countries around the world.
====and=====
Sprott Asset Management picks ATB.to last night on Market Call Tonight

http://www.bnn.ca/articles/rob.tv/52/market_call_tonight.html

Episode
Oct. 9

Guest Focus
Jean-Francois Tardif, sr. portfolio manager, Sprott Asset

Top Picks
Management Alternative investing Northstar Healthcare (NHC)
Atrium Innovations (ATB)
Pure Energy Services (PSV)